Previous 10 | Next 10 |
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 Canada NewsWire Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastati...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
2024-03-27 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...
2024-03-20 16:49:21 ET More on Fusion Pharmaceuticals What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: SMCI, JWN, FUSN, NCMI, crypto stocks and ...
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Fusion Pharmaceuticals Inc. (NASDAQ:...
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates Canada NewsWire Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for...
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Fusion Pharmaceuticals Inc. (NASDAQ:...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 9.8% to $0.133 on volume of 209,262,975 shares Ontrak Inc. (OTRK) rose 131.6% to $0.44 on volume of 206,699,914 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.7% to $3.65 on volume of 1...
2024-03-19 13:15:03 ET Summary AstraZeneca is acquiring Fusion Pharmaceuticals for up to $2.4 billion to expand its presence in the radiopharmaceuticals market. The acquisition includes Fusion's late-stage radiopharmaceutical candidate, FPI-2265, a potential treatment of metastati...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the ...
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Canada NewsWire AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastati...
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Canada NewsWire Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Si...